Appendix 4C – Quarterly Report & Company Update for the period ended 30 September 2016
161031_Appendix 4C – Quarterly Report & Company Update for the period ended 30 September 2016
Second canine receives treatment in trial
161014_SECOND CANINE RECEIVES TREATMENT IN TRIAL
Phase II canine trial begins at the university of Cambridge
160919_PHASE II CANINE TRIAL BEGINS AT THE UNIVERSITY OF CAMBRIDGE
Epichem achieves ISO 90001-2015 certification
161016_EPICHEM ACHIEVES ISO 9001-2015 CERTIFICATION
MPL capsules shipped to centres in NSW & Qld for Phase II
161013_MPL capsules shipped to centres in NSW & Qld for Phase II
PharmAust Investor Presentation – June 2016
160829_PharmAust Investor Presentation – June 2016
Further Canine Trials to be Initiated in Australia
160810_Further Canine Trials to be Initiated in Australia
IP exchange with UNSW consolidates MPL patent position
160803_IP exchange with UNSW consolidates MPL patent position
Reformulated MPL capsules completed, Phase II to commence
160711_Reformulated MPL capsules completed, Phase II to commence
Appendix 4E Annual Report & Full Year Statutory Accounts 2016
160831_Appendix 4E Annual Report & Full Year Statutory Accounts 2016